详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

【已隐藏】The Safety Profile and Preliminary Efficacy of Ceritinib 450mg with Food in Chinese ALK/ROS-1 Positive NSCLC Patients

130| 认领 | 导出 | 链接全文 |

本文已应作者要求隐藏

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Medical Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu/CN, [2]West China Hospital, Sichuan University, Chengdu/CN

出处：

DOI：

ISSN：

关键词： Ceritinib non-small-cell lung cancer Safety

语种：

WOS：

中科院(CAS)分区：

出版当年[2019]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 2 区呼吸系统

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学 1 区呼吸系统

JCR分区：

出版当年[2019]版：

Q1 RESPIRATORY SYSTEM Q1 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY Q1 RESPIRATORY SYSTEM

影响因子： 21.1 最新[2023版] 16.5 最新五年平均 13.357 出版当年[2019版] 10.089 出版当年五年平均 12.46 出版前一年[2018版] 15.609 出版后一年[2020版]

第一作者：

第一作者机构： [1]Department of Medical Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu/CN,

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]塞瑞替尼450 mg随餐服用治疗中国ALK阳性非小细胞肺癌患者的安全性及近期疗效分析 [2]Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC [3]First-line ceritinib versus chemotherapy in patients (pts) with advanced ALK rearranged (ALK1) non-small cell lung cancer (NSCLC): ASCEND-4 Asian subgroup analysis [4]Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6. [5]A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer [6]A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC) [7]Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) [8]Long-term safety of icotinib in patients with non-small cell lung cancer: A retrospective, real-world study(Open Access) [9]Efficacy and Safety of Crizotinib among Chinese EML4-ALK-Positive, Advanced-Stage Non-Small Cell Lung Cancer Patients [10]Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer